MedDataX Logo

Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time

NCT ID: NCT01567852

Last Updated: 2014-12-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

When undergoing ECT treatments, patient recovery time and re-orientation time may be shorter using ketamine for induction than using methohexital.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ECT treatments are done under general anesthesia, and the induction is commonly done with methohexital. We will study whether using ketamine as an induction agent will result in a faster recovery time and quicker re-orientation time compared to using methohexital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-anesthesia Recovery Orientation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

orientation post-anesthesia recovery electroconvulsive therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine First

This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Methohexital

Intervention Type DRUG

Methohexital (1.5mg/kg) will be given for induction

Methohexital First

This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Methohexital

Intervention Type DRUG

Methohexital (1.5mg/kg) will be given for induction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine

Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Intervention Type DRUG

Methohexital

Methohexital (1.5mg/kg) will be given for induction

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients eligible for ECT with a primary mood disorder (bipolar disorder, major depressive disorder) will be eligible to participate in this study. - Patients must have decisional capacity and must be able to consent for this study.

Exclusion Criteria

* patients with a primary psychotic disorder (schizophrenia, schizoaffective disorder); patients designated as having an American Society of Anesthesiologist (ASA) Status of greater than 3;
* patients with a known allergic reactions to methohexital , ketamine and succinylcholine;
* patients with current or previous history of aneurysms, intracranial bleeds, or intracranial hypertension;
* patients with uncontrolled severe hypertension.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of New Mexico

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tony Yen, MD

Role: PRINCIPAL_INVESTIGATOR

University of New Mexico

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of New Mexico

Albuquerque, New Mexico, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HRRC#: 11-236

Identifier Type: -

Identifier Source: org_study_id